Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS - Randomized clinical trial for the treatment of moderate to severe cases of the disease caused by the new coronavirus-2019 with chloroquine and placebo versus chloroquine and colchicine

ABSTRACT: Evaluate efficacy and safety of the use of chloroquine and colchicine in the treatment of hospitalized patients for moderate or severe forms of SARS-CoV-2. Draw a clinical and laboratory profile of the disease in our country. Assess the magnitude of systemic inflammation and possible pathophysiological mechanisms of SARS-CoV-2. The IRB approval number is 30248420.9.0000.5440 (University of Sao Paulo, Brazil)

INSTRUMENT(S): micrOTOF-Q II

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Thiago Mattar Cunha

PROVIDER: MSV000085505 | GNPS | Fri May 29 13:38:00 BST 2020

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Diffuse Alveolar Damage Patterns Reflect the Immunological and Molecular Heterogeneity in Fatal COVID-19

Project description:To date, few studies analyzed the nature of the temporal and spatial cell arrangement during the complex immune/inflammatory/molecular and structural cell alterations that take place in the lungs in severe COVID-19. Such information is crucial to better envision the disease complexity. To this end, we have applied a platform for multiplex imaging complemented with assessment of SARS-CoV-2, bacterial/fungi identification and cytokine/transcriptomic profiling in 18 lungs of deceased patients from Sao Paulo.

2022-08-31 | GSE205099 | GEO

Comparative Pathogenesis of Three Human and Zoonotic SARS-CoV Strains in Cynomolgus Macaques

Project description:The severe acute respiratory syndrome (SARS) epidemic was characterized by increased pathogenicity in the elderly due to an early exacerbated innate host response. SARS-CoV is a zoonotic pathogen that entered the human population through an intermediate host like the palm civet. To prevent future introductions of zoonotic SARS-CoV strains and subsequent transmission into the human population, heterologous disease models are needed to test the efficacy of vaccines and therapeutics against both late human and zoonotic isolates. Here we show that both human and zoonotic SARS-CoV strains can infect cynomolgus macaques and resulted in radiological as well as histopathological changes similar to those seen in mild human cases. Viral replication was higher in animals infected with a late human phase isolate compared to a zoonotic isolate. Host responses to the three SARS-CoV strains were similar and only apparent early during infection with the majority of genes associated with interferon signalling pathways.This study characterizes critical disease models in the evaluation and licensure of therapeutic strategies against SARS-CoV for human use 4 strains, time course, lungs

2011-08-31 | E-GEOD-23955 | biostudies-arrayexpress

Absence of host innate immune responses in SARS-CoV-infected ferrets upon subsequent challenge

Project description:To further investigate the underlying mechanisms of severe acute respiratory syndrome (SARS) pathogenesis and evaluate the therapeutic efficacy of potential drugs and vaccines it is necessary to use an animal model that is highly representative of the human condition in terms of respiratory anatomy, physiology and clinical sequelae. The ferret, Mustela putorius furo, supports SARS-CoV replication and displays many of the symptoms and pathological features seen in SARS-CoV-infected humans. We have recently established a SARS-CoV infection-challenge ferret platform for use in evaluating potential therapeutics to treat SARS. The main objective of the current study was to extend our previous results and identify early host immune responses upon infection and determine immune correlates of protection upon challenge with SARS-CoV in ferrets. Keywords: time course This study is a simple time course (58 day) examination of host responses in 35 SARS-CoV (TOR2) infected ferrets with the addition of a challenge inoculation of SARS CoV (TOR2) at day 29 post infection. Three mock-infected ferrets are included as negative controls. Due to the unavailability of ferret microarrays, Affymetrix Canine 2.0 oligonucleotide arrays were chosen following sequence analysis of our ferret cDNA library (~5000 clones) and demonstration of high levels of homology (>80%) between dog and ferret.

2013-05-28 | E-GEOD-11704 | biostudies-arrayexpress

Trancriptome analysis of peripheral leukocytes from SARS-CoV-2 infected patients and healthy uninfected individuals during the first wave of COVID-19 pandemic in Brazil

Project description:To evaluate the gene expression profiling of peripheral leukocytes in different outcomes of SARS-CoV-2 infections, whole blood samples were collected from individuals with positive SARS-CoV-2 nasopharyngeal swab by RT-PCR (54 patients) and healthy uninfected individuals (12 volunteers). Infected patients were classified into mild, moderate, severe and critical groups according to a modified statement in the Novel Coronavirus Pneumonia Diagnosis and Treatment Guideline. Blood were collected into EDTA tubes and the buffy coat samples were stored in TRIzol reagent at -80 °C until use for RNA extraction. Affymetrix Clariom S array was used to perform the high-throughput gene expression profiling. Microarray analyses were performed using APT Affymetrix software, R packages and Bioconductor libraries. This systemic view of SARS-CoV-2 infections through blood transcriptomics will foster the understanding about molecular mechanisms and immunopathological processes involved in COVID-19 disease and its different outcomes.

2022-04-29 | E-MTAB-11240 | biostudies-arrayexpress

Capturing SARS-cov in low abundant patient samples: a comparative analysis (arbo double ms) .

Project description:In this study, we tested the efficacy of five commercial probes panels at detecting SARS-CoV-2 genome including panels from Illumina, Twist Bioscience and Arbor Bioscience. To do so, we used 19 patient nasal swab samples broken down into 5 series of 4 samples of equivalent SARS-CoV-2 viral load (cycle threshold (CT): low CT means a high viral load – CT26, CT29, CT32, CT35 and CT36+).

2022-06-01 | E-MTAB-11232 | biostudies-arrayexpress

Capturing SARS-cov in low abundant patient samples: a comparative analysis (arbo single MS).

2022-06-01 | E-MTAB-11235 | biostudies-arrayexpress

Capturing SARS-cov in low abundant patient samples: a comparative analysis (Illumina respv NS).

2022-02-08 | E-MTAB-11233 | biostudies-arrayexpress

Capturing SARS-cov in low abundant patient samples: a comparative analysis (Twist sarscov MS).

2022-06-01 | E-MTAB-11234 | biostudies-arrayexpress

Capturing SARS-cov in low abundant patient samples: a comparative analysis (metagenomics NS).

2022-06-01 | E-MTAB-11236 | biostudies-arrayexpress

Capturing SARS-cov in low abundant patient samples: a comparative analysis (twist panviral NS).

2022-06-01 | E-MTAB-11237 | biostudies-arrayexpress